Because of the crosstalk between Src and EGFR, inhibiting the activity of both proteins is feasible and may facilitate the successful treatment of NSCLC patients without EGFR-activating mutations or with acquired resistance-inducing EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.